Company Profile

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE446.55-6.6 (-1.46 % )
PREV CLOSE (Rs.) 453.15
OPEN PRICE (Rs.) 456.80
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 446.55 (25 )
VOLUME 29682
TODAY'S LOW / HIGH (Rs.)446.00 457.30
52 WK LOW / HIGH (Rs.)423.7 711.55
NSE446.55 -6.75 (-1.49 % )
PREV CLOSE(Rs.) 453.30
OPEN PRICE (Rs.) 453.30
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 446.55 (152 )
VOLUME 738913
TODAY'S LOW / HIGH(Rs.) 445.75 457.00
52 WK LOW / HIGH (Rs.)423.65 711.9

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.45
TTM EPS (Rs.) 52.75
P/E Ratio 8.47
Book Value (Rs.) 423.23
Face Value (Rs.) 1
MCap (Rs. in Mn) 126002.19
Price/Earning (TTM) 7.90
Price/Sales (TTM) 2.06
Price/Book (MRQ) 1.06
PAT Margin (%) 15.77
ROCE (%) 11.02
Incorporation Year : 1977

Management Info :

Glenn Saldanha - Chairman Glenn Saldanha - Managing Director

Registered Office :

Address : B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, ,
Mumbai,
Maharashtra-400026

Phone :

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
11Jul07-11-2019$Glenmark Pharma signs licensing agreement with Torrent Pharma Glenmark Pharma signs licens

Glenmark Pharmaceuticals and Torrent Pharmaceuticals have entered into a non-exclusive sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.

Under the terms of the agreement, the company will receive an upfront payment, license fees and royalties for the non-exclusive sub-license rights from Torrent. The company will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark ‘Zucator’ in India.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharmaceuticals and Torrent Pharmaceuticals have enter..
11Jul07-11-2019$Glenmark Pharma surges on signing licensing agreement with Torrent Pharma Glenmark Pharma surges on si

Glenmark Pharmaceuticals is currently trading at Rs. 453.20, up by 7.70 points or 1.73% from its previous closing of Rs. 445.50 on the BSE.

The scrip opened at Rs. 449.70 and has touched a high and low of Rs. 454.15 and Rs. 449.70 respectively. So far 3587 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 711.55 on 10-Sep-2018 and a 52 week low of Rs. 423.70 on 08-Jul-2019.

Last one week high and low of the scrip stood at Rs. 454.90 and Rs. 423.70 respectively. The current market cap of the company is Rs. 12570.59 crore.

The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 39.55% and 13.90% respectively.

Glenmark Pharmaceuticals and Torrent Pharmaceuticals have entered into a non-exclusive sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.

Under the terms of the agreement, the company will receive an upfront payment, license fees and royalties for the non-exclusive sub-license rights from Torrent. The company will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark ‘Zucator’ in India.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharmaceuticals is currently trading at Rs. 453.20, up..
11Jul07-11-2019$Glenmark Pharmaceuticals submits media release Glenmark Pharmaceuticals sub

Glenmark Pharmaceuticals has informed about submission of media release titled ‘Glenmark & Torrent sign licensing agreement for co-marketing of Remogliflozin Etabonate in India’, which is self explanatory.   

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharmaceuticals has informed about submission of media..
09Jul07-09-2019$Glenmark’s arm receives USFDA’s final approval for Ranolazine Extended-Release Tablets Glenmark’s arm receives US

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg, a generic version of Ranexa Extended-Release Tablets, 500 mg and 1,000 mg, of Gilead Sciences, Inc.

According to IQVIA sales data for the 12 month period ending May 2019, the Ranexa Extended Release Tablets, 500 mg and 1,000 mg market achieved annual sales of approximately $929.0 million.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceutic..
09Jul07-09-2019$Glenmark Pharmaceuticals submits media release Glenmark Pharmaceuticals sub

Glenmark Pharmaceuticals has informed about submission of media release titled ‘Glenmark Pharmaceuticals receives ANDA approval for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg’ which is self explanatory. 

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharmaceuticals has informed about submission of media..
Financials More
Rs. in Millions
QTR Mar 19 ANNUAL 19
Net Profit2812.8816221.12
Gross Profit 3581.81 18181.84
Operating Profit 4371.3718030.92
Net Sales 15872.7963048.67
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Procter&Gamble Healt (BSE)
 4904.00 (4.13%)
M.Cap ( in Cr)
8140.34
Sanofi India (BSE)
 5886.70 (0.77%)
M.Cap ( in Cr)
13557.44
Themis Medicare (BSE)
 251.30 (19.98%)
M.Cap ( in Cr)
230.72
Ajanta Pharma (BSE)
 928.70 (2.61%)
M.Cap ( in Cr)
8103.35
Piramal Enterprises (BSE)
 2058.00 (1.04%)
M.Cap ( in Cr)
40922.62
Shareholding Pattern More
PROMOTERS 46.58 %
MUTUAL FUNDS/UTI 4.88 %
FI/BANKS/INSURANCE 2.62 %
NON-INSTITUTION 14.71 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes